Fred Hassan

CIK: 0001110744

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)2 (16.7%)

Derivative conversions

Awards (A)10 (83.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (4)

BBIO

BridgeBio Pharma, Inc.

Director

PGEN

PRECIGEN, INC.

Director

COCP

Cocrystal Pharma, Inc.

Director

EYPT

EyePoint, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (12 total)

BBIO
BridgeBio Pharma, Inc.
Jun 22, 2026
Award(A)
Direct
4K shares-
PGEN
PRECIGEN, INC.
Mar 13, 2026
Exercise(M)
Direct
71.8K shares-
PGEN
PRECIGEN, INC.
Mar 10, 2026
Award(A)
Direct
17.9K shares at avg. $3.51$63K
COCP
Cocrystal Pharma, Inc.
Jan 9, 2026
Award(A)
Stock Options (Right to Buy)
Direct
16.4K shares-
EYPT
EyePoint, Inc.
Jan 2, 2026
Award(A)
Stock Option (Right to Buy)
Direct
40K shares-
COCP
Cocrystal Pharma, Inc.
Oct 28, 2025
Award(A)
Direct
359.7K shares at avg. $1.39$500K
BBIO
BridgeBio Pharma, Inc.
Jun 20, 2025
Award(A)
Direct
6.6K shares-
PGEN
PRECIGEN, INC.
Mar 14, 2025
Exercise(M)
Direct
87.4K shares-
PGEN
PRECIGEN, INC.
Mar 13, 2025
Award(A)
Direct
36.2K shares at avg. $1.74$63K
EYPT
EyePoint Pharmaceuticals, Inc.
Jan 3, 2025
Award(A)
Stock Option (Right to Buy)
Direct
40K shares-
COCP
Cocrystal Pharma, Inc.
Oct 9, 2024
Award(A)
Direct
8.1K shares-
EYPT
EyePoint Pharmaceuticals, Inc.
Sep 3, 2024
Award(A)
Stock Options (Right to buy)
Direct
60K shares-

		Type	Shares	Price		Ownership
Jun 22, 2026	BBIO BridgeBio Pharma, Inc.	Award(A)	3,990	-	$0	Direct
Mar 13, 2026	PGEN PRECIGEN, INC.	Exercise(M)	71,839	-	$0	Direct
Mar 10, 2026	PGEN PRECIGEN, INC.	Award(A)	17,948	$3.51	$62,997	Direct
Jan 9, 2026	COCP Cocrystal Pharma, Inc.	Award(A) Stock Options (Right to Buy)	16,410	-	-	Direct
Jan 2, 2026	EYPT EyePoint, Inc.	Award(A) Stock Option (Right to Buy)	40,000	-	-	Direct
Oct 28, 2025	COCP Cocrystal Pharma, Inc.	Award(A)	359,713	$1.39	$500,001	Direct
Jun 20, 2025	BBIO BridgeBio Pharma, Inc.	Award(A)	6,589	-	-	Direct
Mar 14, 2025	PGEN PRECIGEN, INC.	Exercise(M)	87,412	-	-	Direct
Mar 13, 2025	PGEN PRECIGEN, INC.	Award(A)	36,206	$1.74	$62,998	Direct
Jan 3, 2025	EYPT EyePoint Pharmaceuticals, Inc.	Award(A) Stock Option (Right to Buy)	40,000	-	-	Direct
Oct 9, 2024	COCP Cocrystal Pharma, Inc.	Award(A)	8,067	-	$0	Direct
Sep 3, 2024	EYPT EyePoint Pharmaceuticals, Inc.	Award(A) Stock Options (Right to buy)	60,000	-	-	Direct

1-12 of 12 transactions

About Hassan Fred

Hassan Fred (SEC CIK 0001110744) files insider reports with the SEC as Director of BridgeBio Pharma, Inc. (BBIO), Director of PRECIGEN, INC. (PGEN) and Director of Cocrystal Pharma, Inc. (COCP). Signal8 also holds filings tied to 1 other company.

Signal8 holds 12 ownership filings by Hassan Fred (1 Form 3, 11 Form 4), filed between Sep 5, 2024 and Jun 24, 2026. Those filings report 12 transactions, from Sep 3, 2024 to Jun 22, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Hassan Fred's filings is in PALO ALTO, CA.

Recent filings by Hassan Fred

Jun 22, 2026: Grant or award of BBIO shares (Form 4, code A).
Mar 13, 2026: Option exercise of PGEN shares (Form 4, code M).
Mar 10, 2026: Grant or award of PGEN shares (Form 4, code A).
Jan 9, 2026: Grant or award of COCP derivative securities (Form 4, code A).
Jan 2, 2026: Grant or award of EYPT derivative securities (Form 4, code A).

Other insiders filing for BridgeBio Pharma, Inc. (BBIO)

Kumar Neil, Chief Executive Officer
Trimarchi Thomas, President and CFO
Apuli Maricel, Chief Accounting Officer
Ellis Andrea, Director
Cook Jennifer E., Director
Valantine Hannah, Director

How to read Form 4 transaction codes